轮状病毒疫苗：成功的故事与未来的挑战
Rotavirus Vaccines: a story of success with challenges ahead.
作者信息
O'Ryan Miguel
机构信息
Institute of Biomedical Sciences and Millenium Institute of Immunology and Immunotherapy, Faculty of Medicine, University of Chile, Santiago, Chile.
出版信息
F1000Res. 2017 Aug 18;6:1517. doi: 10.12688/f1000research.11912.1. eCollection 2017.
Abstract
Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive dissemination of rotavirus vaccines worldwide. Currently, 92 countries have introduced rotavirus vaccines into national or subnational programs with evident impact in disease reduction. Two vaccines have been widely used, and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower vaccine efficacy/effectiveness in low-income countries. An additional partially answered issue relates to rotavirus strain circulation in vaccinated populations. These issues are discussed in this review. The most imperative challenge ahead is to fulfill the WHO's recommendation to introduce rotavirus vaccines in all countries.
摘要
自轮状病毒被发现以来，大约已经过去了40年；自轮状病毒疫苗在全球推出并逐步推广以来，也已经过去了10年。目前，92个国家已将轮状病毒疫苗纳入国家或次国家级计划，在减少疾病方面产生了显著影响。两种疫苗已被广泛使用，另外四种疫苗已获许可并在特定地区使用。在此背景下，一个尚未解决的主要问题是低收入国家的疫苗效力/效果较低。另一个部分得到解答的问题与接种疫苗人群中的轮状病毒毒株传播有关。本综述将讨论这些问题。未来最紧迫的挑战是落实世界卫生组织在所有国家引入轮状病毒疫苗的建议。
相似文献
1
Rotavirus Vaccines: a story of success with challenges ahead.
F1000Res. 2017 Aug 18;6:1517. doi: 10.12688/f1000research.11912.1. eCollection 2017.
2
Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
J Infect Dis. 2009 Nov 1;200 Suppl 1:S291-9. doi: 10.1086/605059.
3
Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011.
Curr Opin Virol. 2012 Aug;2(4):434-42. doi: 10.1016/j.coviro.2012.05.002. Epub 2012 Jun 29.
4
Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?
Lancet Infect Dis. 2012 Jul;12(7):561-70. doi: 10.1016/S1473-3099(12)70029-4.
5
Rotavirus vaccines for the developing world.
Curr Opin Infect Dis. 2009 Oct;22(5):483-9. doi: 10.1097/QCO.0b013e32833040a9.
6
Rotavirus vaccines: a story of success.
Clin Microbiol Infect. 2015 Aug;21(8):735-43. doi: 10.1016/j.cmi.2015.01.027. Epub 2015 Feb 11.
7
Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.
J Infect Dis. 2009 Nov 1;200 Suppl 1:S1-8. doi: 10.1086/605061.
8
Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
Expert Rev Vaccines. 2011 Jul;10(7):1037-51. doi: 10.1586/erv.11.65.
9
Rotavirus vaccination: a concise review.
Clin Microbiol Infect. 2012 Oct;18 Suppl 5:57-63. doi: 10.1111/j.1469-0691.2012.03981.x. Epub 2012 Aug 6.
10
Implementing rotavirus vaccination in Asia.
Vaccine. 2007 Nov 1;25(44):7711-6. doi: 10.1016/j.vaccine.2007.07.064. Epub 2007 Aug 22.
引用本文的文献
1
Targeted CRISPR screens reveal genes essential for Cryptosporidium survival in the host intestine.
Nat Commun. 2025 Aug 20;16(1):7749. doi: 10.1038/s41467-025-63012-1.
2
Early-life gut microbiome associates with positive vaccine take and shedding in neonatal schedule of the human neonatal rotavirus vaccine RV3-BB.
Nat Commun. 2025 Apr 11;16(1):3432. doi: 10.1038/s41467-025-58632-6.
3
Immunoinformatics-driven design of a multi-epitope vaccine targeting neonatal rotavirus with focus on outer capsid proteins VP4 and VP7 and non structural proteins NSP2 and NSP5.
Sci Rep. 2025 Apr 7;15(1):11879. doi: 10.1038/s41598-025-95256-8.
4
Gut microbiota in vaccine naïve Gabonese children with rotavirus A gastroenteritis.
Heliyon. 2024 Mar 30;10(7):e28727. doi: 10.1016/j.heliyon.2024.e28727. eCollection 2024 Apr 15.
5
Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses.
Vaccines (Basel). 2023 Nov 28;11(12):1774. doi: 10.3390/vaccines11121774.
6
Comparison of IgA Antibody Titer Induced by Human-Bovine Rotavirus Candidate Vaccine with Bovine Rotavirus and Rotarix.
Arch Razi Inst. 2023 Feb 28;78(1):405-412. doi: 10.22092/ARI.2021.354821.1652. eCollection 2023 Feb.
7
The Complex Interactions Between Rotavirus and the Gut Microbiota.
Front Cell Infect Microbiol. 2021 Jan 8;10:586751. doi: 10.3389/fcimb.2020.586751. eCollection 2020.
8
Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
J Pharm Sci. 2020 Jan;109(1):380-393. doi: 10.1016/j.xphs.2019.08.002. Epub 2019 Aug 7.
9
Birth Cohort Studies Assessing Norovirus Infection and Immunity in Young Children: A Review.
Clin Infect Dis. 2019 Jul 2;69(2):357-365. doi: 10.1093/cid/ciy985.
10
Development of a live attenuated trivalent porcine rotavirus A vaccine against disease caused by recent strains most prevalent in South Korea.
Vet Res. 2019 Jan 7;50(1):2. doi: 10.1186/s13567-018-0619-6.
本文引用的文献
1
Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet Infect Dis. 2017 Sep;17(9):909-948. doi: 10.1016/S1473-3099(17)30276-1. Epub 2017 Jun 1.
2
ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial.
Heliyon. 2017 May 16;3(5):e00302. doi: 10.1016/j.heliyon.2017.e00302. eCollection 2017 May.
3
Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
Vaccine. 2017 Jun 16;35(28):3575-3581. doi: 10.1016/j.vaccine.2017.05.019. Epub 2017 May 20.
4
Parenteral protein-based rotavirus vaccine.
Lancet Infect Dis. 2017 Aug;17(8):786-787. doi: 10.1016/S1473-3099(17)30244-X. Epub 2017 May 5.
5
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Lancet Infect Dis. 2017 Aug;17(8):843-853. doi: 10.1016/S1473-3099(17)30242-6. Epub 2017 May 5.
6
Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016.
Clin Infect Dis. 2017 Sep 1;65(5):840-850. doi: 10.1093/cid/cix369.
7
Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®).
Vaccine. 2017 May 19;35(22):2962-2969. doi: 10.1016/j.vaccine.2017.04.025. Epub 2017 Apr 20.
8
Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea.
J Infect Dis. 2017 Jun 1;215(11):1666-1672. doi: 10.1093/infdis/jix186.
9
Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Clin Exp Immunol. 2017 Sep;189(3):331-341. doi: 10.1111/cei.12977. Epub 2017 May 16.
10
Impact of maternal antibodies and infant gut microbiota on the immunogenicity of rotavirus vaccines in African, Indian and European infants: protocol for a prospective cohort study.
BMJ Open. 2017 Mar 29;7(3):e016577. doi: 10.1136/bmjopen-2017-016577.
Zotero 插件